再生医学的技术进步

Technological Advances in Regenerative Medicine

出版日期: 2024年08月20日 | 出版商:

Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

颠覆性技术和竞争格局推动干细胞治疗研究的成长

再生医学取得了巨大进步，多种干细胞治疗方法现已商业化。研究人员在干细胞治疗方面取得了显着的技术发展，以克服与大规模生产和细胞品质相关的挑战。由于iPS细胞研究的快速发展，干细胞研究已集中在诱导性多功能干细胞上，而不是间质干细胞或造血干细胞。技术平台的开发有助于改善整体干细胞治疗和选择并降低整体成本。新兴企业正在建立更新的细胞分离、表征和筛检流程，以确保恆定的细胞活力和保留。

产业公司越来越多地采用人工智慧和机器学习技术进行干细胞成像、即时追踪和进入新的疾病领域。除了罕见疾病外，干细胞疗法在治疗肿瘤、神经系统疾病和心臟疾病也具有巨大潜力。私人投资和研究合作继续推动干细胞研究和开发，并支持各种疾病的临床试验管道。

本报告重点介绍了相关人员为干细胞疗法开发而设计的渐进技术改进和新平台，包括诱导性多功能干细胞、间质干细胞。

本研究解决的关键问题

干细胞治疗的现况和整体趋势如何？哪些技术发展将改善干细胞疗法的研究和发展？哪些公司正在采用新技术平台来扩大干细胞疗法的研究和发展？干细胞疗法开发的投资和伙伴关係系统是怎么样的？

干细胞疗法开发的持续挑战
干细胞在再生医学开发的临床应用
iPS细胞治疗的进展
间质干细胞的开发
造血干细胞的发育
hESC疗法的发展
干细胞疗法开发商的整体技术实施
支持干细胞开发的细胞製造平台
干细胞选择和表征平台
干细胞治疗开发的人工智慧整合平台
用于干细胞治疗开发的人工智慧平台
干细胞疗法对各种疾病领域的影响

干细胞研究、私人和公共投资的现状

促进干细胞治疗的公共投资趋势
近期私人投资趋势推动干细胞研究
干细胞治疗领域併购增加
扩大伙伴关係

成长机会宇宙

成长机会1：整合人工智慧和自动化以提高干细胞的可扩展性
成长机会2：提升干细胞品质的细胞工程与再程式化方法
增长机会3：先关注癌症，再关注罕见疾病

附录

技术完备等级(TRL)：说明

下一步

成长机会的好处和影响
下一步
免责声明

简介目录

Product Code: DAFE

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mesenchymal and hematopoietic stem cells, a transition caused by the fast-paced developments in iPSC research. Developments in technology platform help improve overall stem cell therapy and selection and reduce overall costs. Emerging companies are establishing newer cell isolation, characterization, and screening processes to ensure constant cell viability and maintenance.

Industry players increasingly adopt artificial intelligence and machine learning technologies for stem cell imaging, real-time tracking, and entering new disease areas. Stem cell therapies have huge potential in treating oncology, neurological conditions, and cardiac conditions, apart from rare diseases. Private investments and collaborations continue to drive stem cell R&D and push the clinical trial pipelines across various diseases.

This report covers incremental technological improvements and the new platforms that stakeholders have designed for stem cell therapy developments in induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and human embryonic stem cells.

Key Questions This Study Addresses:

What is the current landscape of stem cell therapy, and what are the overall trends? What are the technology developments improving stem cell therapy R&D? Which companies are adopting new technology platforms to scale stem cell therapy R&D? What is the investment and partnership ecosystem in stem cell therapy development?

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints
Types of Common Stem Cells in Regenerative Medicine
Overall Trends in Stem Cell Therapy Development
Snapshot of the Regenerative Medicine Landscape

Growth Generator

Ongoing Challenges in the Development of Stem Cell Therapy
Highly Adopted Stem Cells in Clinical Use to Develop Regenerative Medicine
Developments in iPSC Therapies
Developments in MSCs
Developments in HSCs
Developments in hESC Therapies
Overall Technology Adoption by Stem Cell Therapy Developers
Cell Manufacturing Platforms Enabling Stem Cell Development
Stem Cell Selection and Characterization Platform
AI-integrated Platforms for Stem Cell Therapy Developments
AI Platforms for Stem Cell Therapy Development
Impact of Stem Cell Therapies in Various Diseases Areas

Stem Cell Research, Private and Public Investment Landscape

Public Investment Trends Driving Stem Cell Therapy Research
Recent Private Investments Driving Stem Cell Therapy Research
Growing M&As in Stem Cell Therapy
Growing Partnerships

Growth Opportunity Universe

Growth Opportunity 1: Integration of AI and Automation to Improve Stem Cell Scalability
Growth Opportunity 2: Cell Engineering and Reprogramming Methods to Improve Stem Cell Quality
Growth Opportunity 3: Focus on Cancer First and then on Rare Diseases